chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from a nurse concerning a 60 year old male with hypothyroidism and hyperlipidemia as well as no drug allergies who on 29-APR-2009 was vaccinated subcutaneously with a 0.65 ml dose of ZOSTAVAX (Merck) (663894/0129Y).  Concomitant therapy included VYTORIN, LEVOXYL, MSD, hydrochlorothiazide and an unspecified fenofibrate.  On 30-APR-2009 the patient developed shingle-like rashes on the right thoracic in one dermatone.  The patient sought medical attention and was seen by a physician.  At the time of reporting the patient was recovering.  Follow up information was received from the physician concerning the 60 year old male with niacin allergy who on 29-APR-2009 was vaccinated in the right deltoid with a 0.65 year old male with niacin allergy who on 29-APR-2009 was vaccinated in the right deltoid with a 0.65 ml dose of ZOSTAVAX (Merck) (663894/0129Y).  On 30-APR-2009 the patient developed shingle-like rashes on the right thoracic.  The patient was enrolled in a program to identify if VZV is present and if it is present to identify if it is associated with the wild-type (WT) VZV strain or with the Merck vaccine VZV strain.  At the time of reporting the patient was recovering.   It was reported that the patient was not recently exposed to chicken pox or shingles.  The sample of the lesion was collected.  The PCR results for the specimen from rash identified the presence of WT VZV.  Follow up information was received reported that the sample of the lesion was collected on 14-MAY-2009.  The sample was taken from scabs when swabbing.  It was confirmed the patient experienced rash.  VZV DNA was amplified and the PCR results for the specimen from rash identified the presence of Wild Type VZV.  B-globin DNA was not amplified.  Additional information has been requested.
Tiredness; headache; muscle pain; chills; feverish without a fever; joint pain; nausea; swollen throat; diarrhea; vomiting; brand Pfizer-BioNTech COVID-19 Bivalent/ dose number=1; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 58-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 15Dec2022 as dose 1, single (Lot number: GL0446) at the age of 58 years, in left arm for covid-19 immunisation. The patient didn't receive BNT162b2 (BNT162B2). The patient's relevant medical history was not reported. There were no concomitant medications. The following information was reported: FATIGUE (non-serious) with onset 15Dec2022, outcome "recovered", described as "Tiredness"; WRONG PRODUCT ADMINISTERED (non-serious) with onset 15Dec2022, outcome "unknown", described as "brand Pfizer-BioNTech COVID-19 Bivalent/ dose number=1"; CHILLS (non-serious) with onset 15Dec2022, outcome "recovered"; DIARRHOEA (non-serious) with onset 15Dec2022, outcome "recovered", described as "diarrhea"; PYREXIA (non-serious) with onset 15Dec2022, outcome "recovered", described as "feverish without a fever"; HEADACHE (non-serious) with onset 15Dec2022, outcome "recovered"; ARTHRALGIA (non-serious) with onset 15Dec2022, outcome "recovered", described as "joint pain"; MYALGIA (non-serious) with onset 15Dec2022, outcome "recovered", described as "muscle pain"; NAUSEA (non-serious) with onset 15Dec2022, outcome "recovered"; PHARYNGEAL OEDEMA (non-serious) with onset 15Dec2022, outcome "recovered", described as "swollen throat"; VOMITING (non-serious) with onset 15Dec2022, outcome "recovered". Relevant laboratory tests and procedures are available in the appropriate section.  Additional Information: Patient did not receive other vaccine in four weeks. Prior to vaccination the patient was not diagnosed with COVID-19. Patient was tested post vaccination on 16Dec2022 vial nasal swab with negative result.  No follow-up attempts are possible. No further information is expected.
increased appetite; Hot flashes; itching; This is a spontaneous report from a contactable consumer (patient). A 31-year-old female patient (non-pregnant) received 1st dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot: El3302), via an unspecified route of administration on 11Jan2021 18:45 at single dose on left arm for COVID-19 immunisation. The patient medical history was not reported.  There were no concomitant medications. The patient experienced increased appetite, hot flashes and itching, all on 11Jan2021 20:00 with outcome of not recovered. No treatment was received for the events. No COVID prior vaccination. No COVID tested post vaccination. No COVID tested post vaccination.
stiffness of the neck; Weakness in the body; Headaches; a little achiness/feel achy; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 26-Feb-2021 and was forwarded to Moderna on 26-Feb-2021.    This spontaneous case was reported by a consumer and describes the occurrence of MUSCULOSKELETAL STIFFNESS (stiffness of the neck), ASTHENIA (Weakness in the body), PAIN (a little achiness/feel achy) and HEADACHE (Headaches) in an 82-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Feb-2021, the patient experienced PAIN (a little achiness/feel achy). On an unknown date, the patient experienced MUSCULOSKELETAL STIFFNESS (stiffness of the neck), ASTHENIA (Weakness in the body) and HEADACHE (Headaches). At the time of the report, MUSCULOSKELETAL STIFFNESS (stiffness of the neck), ASTHENIA (Weakness in the body), PAIN (a little achiness/feel achy) and HEADACHE (Headaches) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication were reported No treatment medication were reported.
Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 'vaccine administration date; Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 'vaccine administration date; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 'vaccine administration date) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 'vaccine administration date) in a 55-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 066H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 27-Jan-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 27-Jan-2022 at 2:45 PM, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 'vaccine administration date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 'vaccine administration date). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 'vaccine administration date) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 24-Dec-2021 and administered on 'vaccine administration date) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   vaccines went into 2-8 degree Celsius thaw state on or about 20-Dec-2021   No concomitant medication information provided. No treatment medication information provided.
Extreme headache, fever, body aches, extreme chills, and shivering for over two days.
Per EMR documentation: 09/27/13:  trivalent influenza virus vaccine administered. 11/7/13-11/13/13:  Patient complained of febrile illness, found to have increased LFTs. Suspected ehrlichosis, tx empirically with doxycycline x10 days (per ID 12/7/13 Lyme, ehrlichosis labs negative). 11/25/13 back pain with radiation noted, suspected sciatica. 12/2/13: more back pain. 12/7/13 numbness in hands, chest pain, weakness.  12/9/13 left foot numbness (new), 12/14/13: increased leg weakness, hand numbness. 12/16/13 admit to hospital for weakness. Patient treated with IVIG x 5 days (12/17-12/21/13). 12/22/13: discharged with dx of Guillain-Barre syndrome.
Headache, Fever, Diarrhea, NauseaVomiting, sore/swelling injection site, left side of throat partially obstructed, chills, fatigue Narrative: still having diarrhea and fatigue as of writing of this report. all other s/s or vaccine reactions were resolved.
Extreme wheezing, extreme chills, face hot "burning" weakness and aches used Proair - HFA (Albuterol sulfate) and I took 1 non-aspirin acetaminophen caplet and 500mg fell asleep immediately. I don't know if I was exposed to the flu before or if I had reaction to the vaccine. Because during the injection some of the fluid ran down my arm. The following day after the attack -10-19-07 I phoned VAERS - I was told to contact my health provider - contacted 10-19 message center 3 times. After six hours and on my third message I received a response on 10-22-07 had the vaccination read on and its 10-25-07 with no negative reaction. I still have minimal wheezing from the first reaction.
I had no issues with the first Moderna dose, but 5 days after the 2nd dose I experienced chills, dizziness and slight nausea when up and moving.  This lasted 2 days and started going away on day 3, but the dizziness is still slightly  present.  Also, during this time I?ve continually monitored my BP and pulse.  My BP has been elevated averaging around 165/95 (my normal is close to 145/85).  Pulse has been steady averaging around 66-68 which is normal for me.  Today,  my BP is around 150/90 so it?s slowly getting back to normal on day 9 (post vaccine #2).   Also, I had no other symptoms and my temperature was steady at 97 degrees since the vaccination.  Thank you
LOCAL IRRITATION AT INJECTION SITE. VERY RED, SWOLLEN. PT REPORTS NO SYSTEMIC EFFECTS. WILL MONITOR
Patient reports muscle pain at injection site on 11/22/15. Flu shot was given on 9/1/15.
I tested positive on 06/09/2022 I received my 4th dose on 04/22/2022 and my symptoms started on 06/06/2022 sore throat; headaches; fever; chills; lost taste and smell; sweating at night. cough; Diarrhea; and low energy. I went to the walk in clinic on 06/09/2022 where i tested positive. He gave me PAXLOVID ( 5 days) and cough medication with coding 2 or 3 times it didn't help so I stopped. I still cough occasionally but most of my symptoms are gone.
The first night after the injection, I slept straight through the night and did not get up to urinate.  When I woke up in the morning, my urine output was low.  I usually get up 1 to 3 times each night.  The only night I didn?t wake up to urinate was the first night after the Covid vaccine injection.  I have gotten up every night since and every night before the vaccine.
Pt received MENACTRA vaccine (dose #2). Adverse reaction - dizzy, nauseous, pale, took 40 mins to come out of it.
shock react 2-3 hrs p/shot pale, slow breathing, sweating, sl twitching about 5 mins & came out spontaneously;
This spontaneous report as received from a healthcare worker refers to a patient of unknown age and gender. The patient's pertinent medical history and concurrent conditions were not reported. No previous drug reactions or allergies were reported. On an unknown date in December 2014 the patient was vaccinated with first dose of GARDASIL (dosing details were not reported) and on an unknown date in April 2015, second dose of GARDASIL (dosing details were not reported) was administered (inappropriate schedule of drug administration). No concomitant medications were reported. No adverse effects were reported. There was no product quality complaint. Additional information has been requested.
Site: Pain at Injection Site-Medium, Site: Redness at Injection Site-Medium, Systemic: Chest Tightness / Heaviness / Pain-Medium
Information has been received from a physician via a company representative concerning a patient of unknown age and gender. The patient's concurrent conditions, medical history, or concomitant medications were not reported. On 12-JUN-2014, the patient was vaccinated with a dose of PNEUMOVAX 23 2.5 ml, five dose vial, (lot number J004332, with an expiration date of 26-SEP-2014) (route and anatomical location of administration were not reported) that was improperly stored. The lowest temperature excursion was of 32 Fahrenheit (F) (0 Celsius) for a total of 72 hours. The vaccine status was reported as "in excursion". The vaccine storage criteria and the vaccine excursion were reported as "Refrigerator(R)". No adverse effects were reported. Furthermore, no product quality complaint was involved. This is one of several cases from the same reporter. Additional information has been requested.
Tingling and numbness in both arms, hand went numb, feet went numb . Horrible pain and numbness in spine, affected all the nerves in body. Very limited mobility, affecting bodily function.   16 days after first hospital stay, was re-admitted into hospital. Second hospital stay lasted one week.   Given antibiotics   Recommended further testing, no diagnosis given. Feels vaccine activated something that it shouldn't have, "almost killed her."
Injection site pain, body aches, fever, chills, tiredness until 6:00pm on 3/21/2021
Dry Mouth Narrative: Patient reported body aches and joint pain as well as dry mouth after receiving the first dose of vaccine.
Fever, nausea, chills, body  aches, vomiting for 2 days.
Arexvy adjuvant was administered without being reconstituted with the lyophilized antigen portion; Arexvy adjuvant was administered without being reconstituted with the lyophilized antigen portion; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of inappropriate preparation of medication in a patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis.   On 01-SEP-2023, the patient received Arexvy. On 01-SEP-2023, an unknown time after receiving Arexvy, the patient experienced inappropriate preparation of medication (Verbatim: Arexvy adjuvant was administered without being reconstituted with the lyophilized antigen portion) and inappropriate dose of vaccine administered (Verbatim: Arexvy adjuvant was administered without being reconstituted with the lyophilized antigen portion). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown.   Additional Information: GSK Receipt Date: 05-SEP-2023 The reporter stated that a peer contacted him stating they believed that a dose of Arexvy adjuvant was administered without being reconstituted with the lyophilized antigen portion, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. They were going back to watch video evidence to determine which patient it was and when it occurred. At this time, no additional information was available. The reporter consented to follow up.
At 11:15am, patient received  first dose of SARS-CoV-2  vaccine. At 12:00pm, patient began to develop a rash and had mild edema noted in the uvula. She did not have difficulty breathing/swallowing/speaking. She was given prednisone 50mg x 1 and diphenhydramine 50mg x 1 in the ED.
Pt left clinic without incident, Registrar received call from mother stated as patient was in auto, vomited and became pale denies rash, angioedema, respiratory difficulty, pt. coherent and responsive mother returned to lobby of building within 10 minutes evaluated by myself and RN pt responsive, oriented,  active, normal respiratory rate, pulse 88.
Arthralgia, Rash, HIVES -SOME WITH PUSTULES/INTERMITTENT ITCHINESS, DYSPNEA AND DURING CONVERSATION/DIFFICULTY WITH LONG WALKS/HX ASTHMA Narrative: 2/1/2021 SEEN AT OCC HEALTH R/T HIVES AND RECOMMENDED BENDRYL THAT NIGHT AND F/U IN 2 DAYS. 2/3/2021-SEEN BY PROVIDER FOR F/U AND RECOMMENDED TO SEE PCP R/T RESP ISSUES. REMAINED WORKING THAT DAY. 2/5/2021-RETURNED TO DUTY AND WAS PUT ON PREDNISONE/PCP.
Patient stayed for 30 minute observation after vaccine was given; patient complained of itching on nose, arms, back, legs and ears at the 30 minutes.  Patient was given 25 mg of diphenhydramine IM.  Patient observed for 30 minutes more and says she was feeling better.  Follow up on patient on 2/16/21  patient says she took another Benadryl when she got home and slept well and had no issues.
Information has been received from a physician concerning a 12 weeks old male patient who was born pre-term at 34 weeks and on 31-MAR-2009 was vaccinated orally with the first dose of ROTATEQ.  Since 05-APR-2009 the patient has been experiencing six watery stools per day.  A stool culture was performed.  Results were not reported.  The patient was seen at the practice.  The physician reported that the patient's sibling also received ROTATEQ and was experiencing the same adverse event (WAES # 0904USA03411).  Follow-up information was received from a nurse who reported that both patients received ROTATEQ vaccine (lot # 663400/1693X).  It was reported that they have not yet received the patient's stool culture results.  The nurse did not know the patient's current status.  Follow up information received on 28-MAY-2009 from a physician stated that the patient experienced diarrhea for 2 weeks and the stool culture done to rule out bacteria as the cause of diarrhea was negative.  The patient recovered approximately on 24-APR-2009.  This is one of two reports from the same source.  No further information is available.
Day after vaccination fell backwards in parking lot trying to get into car. Hit head. Taken to ER.  CT/MRI of brain showing evidence of 3rd ventricle and left lateral ventricle intracranial hemorrhage.
Presented w/ c/o feeling lightheaded and chest tightness, hands sweaty.  B/P 126/67, HR 104, O2 sat 99%. 5:09 pm B/P 122/71, HR 106, ECG strip NSR. 5:25 pm Palms dry HR decreased to 98, stated lightheadedness subsided.  States she gets anxious and just wanted to be checked.  Advised if symptoms returned, pull over safety and call 911.  Said she was going home to relax w. hot bath and sit on patio.
Patient got Boostrix instead of Kinrix; 4 yo pt inadvertently given Boostrix; This case was reported by a physician via sales rep and described the occurrence of wrong vaccine administered in a 4-year-old male patient who received DTPa (Reduced antigen) (Boostrix) for prophylaxis.   On an unknown date, the patient received Boostrix. On an unknown date, unknown after receiving Boostrix, the patient experienced wrong vaccine administered and inappropriate age at vaccine administration. On an unknown date, the outcome of the wrong vaccine administered and inappropriate age at vaccine administration were unknown.  Additional details were provided as follows: The physician reported that a 4 year old boy inadvertently received Boostrix instead of Kinrix, which led wrong vaccine administered and inappropriate age at vaccine administration. The Centers for Disease Control and Prevention (CDC) guidance was provided. The reporter consented to follow-up.
Systemic: Dizziness / Lightheadness-Mild, Systemic: Flushed / Sweating-Mild, Additional Details: Patient stated that he feels lightheadedness and upon touch, he feels clampy. Advised him to lie down (his mom holding him), and then checked his blood pressure. His blood pressure is on a lower side 89/60 with pulse around 46.  He ate breakfast (cereal and banana) at 8am and the vaccine was given at 12:00pm. His blood sugar might be low (but cannot confirm since we do not have the authority to do blood sugar check).  I gave the patient some Pedialyte which has electrolytes and sugar.
lt arm swollen & red, hot to touch;pt felt weak & nervous;no temp;visit to MD recommended;ice pack, claritan & Ibuprofen & DPH;
Information has been received from a registered pharmacist concerning a male patient who on an unspecified date was vaccinated with PNEUMOVAX 23 (lot number not reported). When the nurse withdrew the needle from the patient, half of the medication squirted out of the syringe. The nurse gave the PNEUMOVAX 23 intramuscularly to the patient. The patient was approximately 330lbs. No adverse reactions reported. Additional information has been requested.
The night of the second dose vaccination  I got a fever of 100.1-101 which lasted for three days. I had a cough, fatigue, a mild headache and a cough. I also had nausea and diarrhea. The fatigue, coughing and severe tiredness lasted for a week. For about three weeks after the shot I had intermittent symptoms of fever at night. It was not every day. I had similar symptoms after the first dose. A fever for 24 hours and the tiredness for two days.
3 hours - aches and fever started 3 hours to 3 days - fever randomly 99 to 102, aches, extreme fatigue, dry cough 3 days to 7 days - fever randomly 99 to 101, sinus congestion, slightly productive cough After 7 days - chest cough continued for 1 week, sinus infection continued for about 2 weeks
Fasting glucose was 175 the morning after; first dose: 20Jul2021 second dose: 20Jul2021; This is a spontaneous report from a contactable consumer (patient). A 58-year-old non-pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), via an unspecified route of administration, administered in arm left on 20Jul2021 15:30 (Batch/Lot Number: FA6780) (at age 58-years-old) as dose 1, single, then via an unspecified route of administration, administered in arm left on 20Jul2021 (Batch/Lot Number: FA7484) as dose 2, single for covid-19 immunisation. There were no medical history. Concomitant medication(s) included hydrochlorothiazide (HTZ); beta vulgaris, folic acid, malus spp. vinegar extract, punica granatum, vitamin b12 nos (GOLI); and multivitamin (CENTRUM).  There were no ther vaccines received within 4 weeks. The patient experienced fasting glucose was 175 the morning after on 11Aug2021 06:30. Fasting is normally between 125 and 135.  Following morning, results was in range. Outcome of the event of fasting glucose increased was recovered on Aug2021. No treatment was received. Patient had no covid prior to vaccination and had not been tested post vaccination.